18 Lymphoma Clinical Trials in Seattle, WA (2026)

Q: How do I join a clinical trial in Seattle?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Seattle research site will contact you.

Recruiting Lymphoma Studies in Seattle

NCT06542250Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Ma...

Seattle, WAPHASE1174 participantsAstraZeneca

View Study Details

NCT06745076Recruiting

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

This phase II trial tests how well personalized reduction of chemotherapy (nivolumab, doxorubicin, vinblastine and dacarbazine) based on circulating tumor deoxyribonucleic acid (ctDNA) evaluation work...

Seattle, WAPHASE2125 participantsUniversity of Washington

View Study Details

NCT06528301Recruiting

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymp...

Seattle, WAPHASE1106 participantsUmoja Biopharma

View Study Details

NCT04669171Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide an...

Seattle, WAPHASE180 participantsEnterome

View Study Details

NCT05237986Recruiting

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about ...

Seattle, WA60 participantsNational Cancer Institute (NCI)

View Study Details

NCT04231877Recruiting

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy with or without glofitamab for the treatment of patients with untreated large B-cell lymphom...

Seattle, WAPHASE156 participantsUniversity of Washington

View Study Details

NCT05905328Recruiting

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with ...

Seattle, WAPHASE154 participantsCytoAgents, Inc.

View Study Details

NCT07225985Recruiting

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

This phase I/II trial studies the side effects and best dose of pralatrexate in combination with bendamustine and total-body irradiation (TBI) followed by a donor stem cell transplant in treating pati...

Seattle, WAPHASE150 participantsFred Hutchinson Cancer Center

View Study Details

NCT04626791Recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line...

Seattle, WAPHASE245 participantsAcademic and Community Cancer Research United

View Study Details

NCT07121946Recruiting

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity...

Seattle, WAPHASE142 participantsLTZ Therapeutics, Inc.

View Study Details

NCT05370430Recruiting

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)...

Seattle, WAPHASE136 participantsPeproMene Bio, Inc.

View Study Details

NCT07098364Recruiting

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

This phase I/II trial tests the safety, side effects, and best dose/regimen of ST-067 in combination with CD19-directed chimeric antigen receptor (CAR) T-cell therapy (liso-cel) and how well it works ...

Seattle, WAPHASE133 participantsFred Hutchinson Cancer Center

View Study Details

NCT06175000Recruiting

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer ...

Seattle, WAPHASE228 participantsProvidence Health & Services

View Study Details

NCT06784726Recruiting

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back...

Seattle, WAPHASE227 participantsUniversity of Washington

View Study Details

NCT06948786Recruiting

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

This phase II trial tests how well pirtobrutinib and mosunetuzumab work in treating patients with grade 1-3a follicular lymphoma (FL) that has come back after a period of improvement (relapsed) or tha...

Seattle, WAPHASE222 participantsUniversity of Washington

View Study Details

NCT07194980Recruiting

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This phase II trial studies how well the addition of nemtabrutinib to lisocabtagene maraleucel in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has come...

Seattle, WAPHASE220 participantsFred Hutchinson Cancer Center

View Study Details

NCT06442475Recruiting

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may...

Seattle, WAPHASE220 participantsUniversity of Washington

View Study Details

NCT07097363Recruiting

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

This phase II trial tests the safety, best dose, and effectiveness of epcoritamab when given with etoposide, cyclophosphamide, vincristine, doxorubicin, prednisone and rituximab (EPOCH-R) for the trea...

Seattle, WAPHASE218 participantsUniversity of Washington

View Study Details

About Lymphoma Clinical Trials in Seattle

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 18 lymphoma clinical trials recruiting participants in Seattle, WA. These studies are seeking a combined 996 participants. Research is being sponsored by AstraZeneca, University of Washington, Umoja Biopharma and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in Seattle — FAQ

Are there lymphoma clinical trials in Seattle?

Yes, there are 18 lymphoma clinical trials currently recruiting in Seattle, WA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Seattle?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Seattle research site will contact you about next steps.

Are clinical trials in Seattle free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Seattle studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 18 active trials in Seattle are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated July 16, 2026 from ClinicalTrials.gov